Literature DB >> 6789358

Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.

C C Huang, R I Wang, A Hasegawa, L Alverno.   

Abstract

Thirty inpatients with evidence of tardive dyskinesia secondary to antipsychotic medications participated in this double-blind, controlled, randomized study comparing reserpine, alpha-methyldopa and placebo. Reserpine at doses of 0.75--1.5 mg daily, or alpha-methyldopa at doses of 750--1,500 mg daily, produced a statistically significant improvement in tardive dyskinesia symptomatology compared to the results obtained with placebo.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6789358     DOI： 10.1007/BF00426466

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  20 in total

1.  EFFECT OF ALPHA-METHYL DOPA AND RESERPINE IN HUNTINGTON'S CHOREA, PARKINSON'S DISEASE AND OTHER MOVEMENT DISORDERS.

Authors:  C H MARKHAM; W G CLARK; W D WINTERS
Journal:  Life Sci (1962)       Date:  1963-09

2.  Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca.

Authors:  E BRANDRUP
Journal:  Am J Psychiatry       Date:  1961-12       Impact factor: 18.112

3.  Serotonin release as a possible mechanism of reserpine action.

Authors:  A PLETSCHER; P A SHORE; B B BRODIE
Journal:  Science       Date:  1955-08-26       Impact factor: 47.728

4.  Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.

Authors:  H Kazamatsuri; C Chien; J O Cole
Journal:  Arch Gen Psychiatry       Date:  1972-07

5.  Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.

Authors:  H Kazamatsuri; C Chien; J O Cole
Journal:  Arch Gen Psychiatry       Date:  1972-07

Review 6.  Theoretical implications of the use of L-dopa in parkinsonism. A review.

Authors:  H Klawans; M M Ilahi; D Shenker
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

7.  Treatment of drug-induced dyskinesias.

Authors:  A Villeneuve; Z Böszörményi
Journal:  Lancet       Date:  1970-02-14       Impact factor: 79.321

8.  Mediocre effects of reserpine on tardive dyskinesia.

Authors:  G E Crane
Journal:  N Engl J Med       Date:  1973-01-11       Impact factor: 91.245

9.  Reserpine for tardive dyskinesia.

Authors:  R C Duvoisin
Journal:  N Engl J Med       Date:  1972-03-16       Impact factor: 91.245

10.  Persistent dyskinesias following phenothiazine therapy. Report of five cases and a review of the literature.

Authors:  W R Schmidt; L W Jarcho
Journal:  Arch Neurol       Date:  1966-04
View more
  6 in total

1.  Tardive Dyskinesia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Tardive dyskinesia.

Authors:  Pratibha G Aia; Gonzalo J Revuelta; Leslie J Cloud; Stewart A Factor
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

Review 4.  Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

Authors:  Karla Soares-Weiser; John Rathbone; Yusuke Ogawa; Kiyomi Shinohara; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 5.  Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

Authors:  Hany G El-Sayeh; John Rathbone; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-01-18

6.  Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.

Authors:  Jungjin Kim; Eric Macmaster; Thomas L Schwartz
Journal:  Drugs Context       Date:  2014-04-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.